Evidence map›Paper›PMID 40790600›Full record

ReviewEuropean journal of medical research2025

From bench to bed: deep insights the tacrolimus-induced diabetes and gut microbiota dysbiosis.

Yuting Han, Zhiying Bian, Jiatong Zhao, Haiying Xiao, Hongyu Wang, Fei Gao, Weikai Shi, JinJin Liu, Jingdong Xu, Chun Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuting Han *Department of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Zhiying Bian *Department of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Jiatong Zhao *Department of Clinical Medicine, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.
Haiying XiaoDepartment of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Hongyu WangDepartment of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Fei GaoDepartment of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Weikai ShiDepartment of Clinical Medicine, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.
JinJin LiuDepartment of Endocrinology, First Affiliated Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Jingdong XuDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China. xujingdong@163.com.
Chun XuDepartment of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. xuchh2000-1@163.com.

Funding

National Science and Technology Major Project 2024ZD0532301the Special Fund for Discipline Innovation and Development of the Third Medical Center of Chinese PLA General Hospital 2024BJ-14The Traditional Chinese and Western Medicine Collaborative Chronic Disease Management Research Project Fund CXZH2024080
6 · The paper itself

Abstract

The gut-liver axis is particularly vulnerable, and the alterations in gut microbiota composition have been linked to post-transplant complications. Liver transplantation is a life-saving procedure for patients with end-stage liver disease, but post-transplant complications are common and can significantly impact long-term outcomes. Tacrolimus is a widely used immunosuppressive agent in liver transplantation, primarily aimed at preventing graft rejection and promoting long-term graft survival. However, its effects on gut microbiota and the subsequent metabolic consequences remain underexplored. In this review, we will synthesize the latest findings on the effects of tacrolimus on gut microbiota in liver transplant patients and discuss how these changes may contribute to the development of diabetes and insulin resistance. By elucidating the interplay between tacrolimus, gut microbiota, and metabolic health, we aim to provide insights into potential therapeutic strategies for improving post-transplant outcomes.

Indexed as

Diabetes MellitusDysbiosisGastrointestinal MicrobiomeImmunosuppressive AgentsLiver TransplantationTacrolimusGraft RejectionHumansImmunosuppressive AgentsTacrolimusDiabetesGut microbiotaInsulin resistanceLiver transplantationMetabolitesTacrolimus

Identifiers

PMID40790600
PMCPMC12337519

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.